Mark Purcell
Stock Analyst at Morgan Stanley
(1.41)
# 3,528
Out of 5,042 analysts
6
Total ratings
66.67%
Success rate
-3.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Upgrades: Overweight | $56 → $58 | $50.58 | +14.67% | 2 | Sep 8, 2025 | |
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $123.79 | -7.91% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $46.86 | -6.10% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $82.40 | +3.16% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $49.46 | +142.62% | 1 | Jan 23, 2024 |
Sanofi
Sep 8, 2025
Upgrades: Overweight
Price Target: $56 → $58
Current: $50.58
Upside: +14.67%
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $123.79
Upside: -7.91%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $46.86
Upside: -6.10%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $82.40
Upside: +3.16%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $49.46
Upside: +142.62%